{"id":775782,"date":"2023-08-07T07:09:43","date_gmt":"2023-08-07T11:09:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/new-publication-highlights-the-ability-of-the-tissuecypher-barretts-esophagus-test-to-improve-and-standardize-the-clinical-management-of-low-grade-dysplasia-in-patients-with-barrett\/"},"modified":"2023-08-07T07:09:43","modified_gmt":"2023-08-07T11:09:43","slug":"new-publication-highlights-the-ability-of-the-tissuecypher-barretts-esophagus-test-to-improve-and-standardize-the-clinical-management-of-low-grade-dysplasia-in-patients-with-barrett","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/new-publication-highlights-the-ability-of-the-tissuecypher-barretts-esophagus-test-to-improve-and-standardize-the-clinical-management-of-low-grade-dysplasia-in-patients-with-barrett\/","title":{"rendered":"New Publication Highlights the Ability of the TissueCypher\u00ae Barrett\u2019s Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett\u2019s Esophagus"},"content":{"rendered":"

<\/p>\n

New Publication Highlights the Ability of the TissueCypher\u00ae Barrett\u2019s Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett\u2019s Esophagus<\/b><\/p>\n

In the study, management decisions were simulated to determine the most likely care plan with or without use of the TissueCypher test for guidance<\/i><\/p>\n

Study data shows TissueCypher test results significantly improved the likelihood of appropriate management and the consistency of management decisions<\/i><\/p>\n

FRIENDSWOOD, Texas–(BUSINESS WIRE<\/a>)–
\nCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a new study published in The American Journal of Gastroenterology<\/i> showing how use of TissueCypher\u00ae Barrett\u2019s Esophagus test results can significantly improve management decisions for Barrett\u2019s esophagus (BE) patients with low-grade dysplasia (LGD)to improve health outcomes. The full study is available here<\/a>.<\/p>\n

\n\u201cA significant challenge in the clinical management of Barrett\u2019s esophagus is the inconsistency in diagnoses, and thus patient management, when relying solely on pathology review of biopsied tissue,\u201d said Jacques Bergman, M.D., Ph.D., study author, leading BE expert and Professor of Gastrointestinal Endoscopy at the University of Amsterdam and the Amsterdam University Medical Centers, the Netherlands. \u201cAs demonstrated in this study, TissueCypher test results offer a tool that may alleviate this challenge by providing objective and actionable risk-stratification that can improve patient care decisions, including the upstaging of care for high-risk patients and the downstaging of care for patients who are at low-risk for progression to more advanced dysplasia or esophageal cancer.\u201d<\/p>\n

\nThe study involved a cohort of 154 real patients with community-based LGD and known progression\/non-progression outcomes who were followed prospectively as part of the Surveillance versus Radiofrequency Ablation (SURF) trial. Management decision simulations were performed to determine the most likely care plan with or without use of TissueCypher, where each patient\u2019s specimens were reviewed by 30 pathologists, leading to confirmation of dysplasia or downstaging to non-dysplastic Barrett\u2019s esophagus (NDBE) or indefinite for dysplasia (IND). The study results showed the following:<\/p>\n